A technology for inhibiting Hepatitis E virus by targeting and screening the ORF3 viroporin protein

Background

Hepatitis E virus (HEV) is a significant cause of acute viral hepatitis globally, with a particularly high burden in developing regions where sanitation is poor and waterborne outbreaks are common. While most HEV infections are self-limiting, the virus can cause severe and even fatal disease in certain populations, such as pregnant women and immunocompromised individuals, including organ transplant recipients and people living with HIV. The limited availability of effective vaccines and the contraindications or limited efficacy of current antiviral treatments, such as pegylated interferon and ribavirin, create a pressing need for new therapeutic options. The emergence of ribavirin-resistant HEV strains further exacerbates this challenge, highlighting the necessity for alternative strategies to manage and treat HEV infections.

Current approaches to HEV treatment are hampered by several critical limitations. Pegylated interferon is not suitable for many patients due to its side effect profile and contraindications, especially in pregnant women. Ribavirin, although sometimes effective, is associated with the development of resistant viral isolates and is also contraindicated in pregnancy due to teratogenicity. Furthermore, the lack of broadly accessible and effective vaccines leaves large populations vulnerable to infection and outbreaks. Existing antiviral therapies do not specifically target viral proteins essential for HEV egress and propagation, limiting their effectiveness and contributing to persistent gaps in HEV management, particularly for chronic or severe cases. As a result, there is a substantial unmet need for novel therapeutic approaches that can safely and effectively inhibit HEV replication and transmission.

Technology

This technology provides a targeted approach to inhibiting Hepatitis E virus (HEV) by disrupting the function of the viral open reading frame 3 (ORF3) protein, which acts as a viroporin—an ion channel essential for the release of infectious viral particles from host cells. The system employs small molecules or peptides that specifically bind to and block critical amino acid regions within ORF3, thereby preventing its ion channel activity, multimerization, and subsequent viral egress. To facilitate the discovery of effective inhibitors, a transcomplementation screening assay is incorporated, utilizing nucleic acids encoding HEV structural and non-structural proteins along with a reporter gene. This assay enables rapid quantification of viral infectivity and identification of compounds that successfully inhibit ORF3 function, supporting both therapeutic development and mechanistic studies.

The differentiation of this technology lies in its precise molecular targeting and innovative screening methodology. Unlike existing treatments such as ribavirin or interferon—which have limited efficacy, significant side effects, and are unsuitable for certain populations—this approach directly interferes with a unique and essential step in the HEV lifecycle. By focusing on the viroporin activity of ORF3, which is critical for viral particle release but not present in host proteins, the technology offers high specificity and reduced risk of off-target effects. Furthermore, the transcomplementation assay provides a robust, scalable platform for high-throughput screening of candidate inhibitors, accelerating the identification of new therapeutics. This comprehensive strategy addresses the urgent need for effective HEV treatments, especially for vulnerable groups such as immunocompromised patients and pregnant women, and is adaptable to multiple HEV genotypes.

Benefits

• Effectively inhibits Hepatitis E virus (HEV) by targeting the essential ORF3 viroporin protein, blocking viral egress and infectivity.
• Provides novel therapeutic options for treating HEV infections, including in vulnerable populations such as pregnant women and immunocompromised patients.
• Utilizes small molecules or peptides that specifically disrupt critical functional regions of ORF3, enhancing treatment specificity and efficacy.
• Includes a robust transcomplementation screening assay to identify and evaluate new anti-HEV agents efficiently.
• Offers potential for combination therapy with existing antiviral agents, expanding treatment versatility.
• Applicable to multiple HEV genotypes, supporting broad-spectrum antiviral development.
• Supports various administration routes and pharmaceutical formulations for flexible clinical use.

Applications

• HEV antiviral drug development
• HEV therapeutic treatment formulations
• High-throughput screening for HEV inhibitors
• Diagnostic assays for HEV infectivity

Additional info

This technology inhibits Hepatitis E virus by targeting the ORF3 transmembrane viroporin. Small molecules or peptides disrupt ion channel activity at specific residues, including 11-13 and 95-98, blocking viral egress. A transcomplementation screening assay using ORF2, ORF3, and reporter-fused ORF1 identifies inhibitory agents. By suppressing ORF3’s viroporin function, these methods provide a therapeutic mechanism for treating viral infections in human and mammalian subjects.